MMprofilerTM with SKY92
Our lead product MMprofilerTM, is a clinical test used to aid physicians in the prognosis of multiple myeloma (blood cancer). It measures the activity of 92 cancer genes (SKY92), and is the most reliable test on the market to determine a patient’s prognosis. The MMprofilerTM with SKY92 is available as CE-IVD kit in Europe and as a CLIA validated Laboratory Developed Test (LDT) in the United States.
Discover MMprofilerTM here (info & references)!
Machine learning algorithm GESTURETM
GESTURETM identifies patients that share genetic similarities in their diseased cells, but have received different treatments. The algorithm learns from each patient’s response to the designated treatment. Based on those parameters, GESTURETM builds a proprietary biomarker that correlates genetic information from the diseased cell with treatment outcome. This biomarker can then be developed into a diagnostic test that predicts, at diagnosis, which treatment will be the most beneficial for individual patients. GESTURETM can be used for any disease with sufficient available (patient) data and is scientifically validated for the blood cancer multiple myeloma.
Discover GESTURETM publication in Nature Communications (Ubels et al, 2018) here!
The AMLprofilerTM aids physicians in accurately diagnosing patients suffering from acute myeloid leukemia (blood cancer), and makes a distinction between various genetic forms for an optimal therapy strategy. Furthermore, the AMLprofilerTM delivers a faster result. It replaces seven separate diagnostic tools, and reduces the time between sampling and diagnosis from 4 weeks to 3 days. The AMLprofilerTM is available as CE-IVD kit in Europe.